Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice

doi: 10.1007/s00262-007-0317-0

Figure Lengend Snippet: Fate of injected IL-2 activated NK cells; 4 × 106 CFSE-labeled NK cells were iv injected in groups of 3 NOD/scid mice. Animals were terminated at different times pi. A Cytofluorimetric analysis of in vitro IL-2 activated NK cells demonstrating their purity. B Blood, bone marrow flushed from femurs, and spleen cell suspensions analyzed by flow cytometry. Percentages of CFSE-labeled NK cells (green) with respect to total white blood cell count are indicated. CTR was represented by cells derived from mice injected with unlabelled polyclonal NK cells. C Fluorescence microscopic analysis of cryostat sections of lung (a, b), liver (c, d), kidney (e, f) and bone marrow smears (g, h) at ×20 (a, c, e, g) and ×100 (b, d, f, h) magnification, respectively. Samples were from mice terminated at 24 h pi; CFSE-labeled NK cells (green), organ cells (blue)

Article Snippet: NK cells were purified from PBL of healthy donors using the Human NK Cell Enrichment Cocktail-RosetteSep (StemCell Technologies Inc, Vancouver, BC, Canada) and cultured on irradiated feeder cells in the presence of 100 IU/mL human recombinant (hr)IL2 (Proleukin, Chiron Corp., Emeryville, USA) and 1.5 ng/mL Phytohemagglutinin (PHA) (Gibco Ltd, Paisley, UK) in order to obtain polyclonal NK cell populations.

Techniques: Injection, Labeling, In Vitro, Flow Cytometry, Cell Counting, Derivative Assay, Fluorescence

Journal: Cancer Immunology, Immunotherapy : CII

Article Title: Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice

doi: 10.1007/s00262-007-0317-0

Figure Lengend Snippet: Therapeutic effects of NK cell infusions. Panel a four groups of 7, 5-week-old, NOD/scid mice were iv injected with 1 × 106 HTLA-230 cells, then animals were treated with medium alone (circle) or with 4 × 106 polyclonal NK cells at 24 h pi (square), at 4, 24 and 48 h pi (triangle) or at 4, 24, 48 and 96 h pi (plus sign). Panel b four groups of 7, 5 week-old, NOD/scid mice were iv injected with 1 × 106 HTLA-230 cells, then animals were treated at 0, 4, 24 and 48 h pi with medium alone (circle), with 4 × 106 polyclonal NK cells (square), with 4 × 106 polyclonal NK cells + hrIL2 (triangle) or 4 × 106 polyclonal NK cells + hrIL15 (plus sign). Panel c IL2-activated NK cells from donor #1 were cultured in the absence or in the presence of rhIL2 (100 IU/mL) and rhIL15 (50 ng/mL). After 3 days, cells were stained with mAbs specific for the indicated molecules, followed by PE-conjugated goat anti-mouse isotype-specific second reagent and analyzed by flow cytometry. Sketched profiles cells incubated with second reagent alone, white profiles cells cultured without cytokines, grey profiles cells cultured with the indicated cytokine. Panel d Five groups of 7, 5-week-old, NOD/scid mice were iv injected with 1 × 106 HTLA-230 cells, then animals were treated with medium alone (circle), with 4 × 106 polyclonal NK cells + hr IL2 at 0 h pi (square), with 4 × 106 polyclonal NK cells + hr IL15 at 0 hr pi (triangle), with 100 ng/mouse hrIL2 at 0, 4, 24 and 48 h pi (plus sign) or with 50 ng/mouse hrIL15 at 0, 4, 24 and 48 h pi (multiple sign). All the experiments were performed twice with similar results

Article Snippet: NK cells were purified from PBL of healthy donors using the Human NK Cell Enrichment Cocktail-RosetteSep (StemCell Technologies Inc, Vancouver, BC, Canada) and cultured on irradiated feeder cells in the presence of 100 IU/mL human recombinant (hr)IL2 (Proleukin, Chiron Corp., Emeryville, USA) and 1.5 ng/mL Phytohemagglutinin (PHA) (Gibco Ltd, Paisley, UK) in order to obtain polyclonal NK cell populations.

Techniques: Injection, Cell Culture, Staining, Flow Cytometry, Incubation

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Article Title: Novel BAFF-receptor antibody to natively folded recombinant protein eliminates drug resistant human B-cell malignancies in vivo

doi: 10.1158/1078-0432.CCR-17-1193

Figure Lengend Snippet: (A) Treatment schedule following Day 0 tumor challenge with minimum lethal dose of tumors. Antibody treatments were given by IV tail vein injections: 200 μg treatment antibody, 10 × 106 effector human NK-92-176V cells, and 5 × 104 IU IL-2. Bioluminescence imaging monitored mice challenged with luciferase-expressing tumors: (B) JeKo-1 (MCL) or (C) RS4;11 (ALL). Experimental groups received treatment of chimeric BAFF-R mAbs (C55 or C90, as indicated). Control group mice received PBS, NK cells alone, or rituximab on the same schedule. Data are representative of three independent experiments.

Article Snippet: Treatments were 300 μL IV injection: 200 μg treatment antibody, 10 × 10 6 effector human NK-92-176V cells, and 5 × 10 4 IU IL-2 (Prometheus Laboratories, San Diego, CA).

Techniques: Imaging, Luciferase, Expressing